Boehringer Ingelheim to build biopharma facility in China

7 June 2013

German family-owned drug major Boehringer Ingelheim has signed a strategic alliance agreement and contract to build a current Good Manufacturing Practices (cGMP) biopharmaceuticals facility with China’s Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base) in Pudong, Shanghai.

The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology, the drugmaker said.

The facility set up will include technical process development and GMP manufacturing which will be ready for operations early 2016. Boehringer Ingelheim plans an investment of over 35 million euros ($45.2 million). The project will create up to 65 job opportunities with high qualification standards.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK